NCT00424710View on ClinicalTrials.gov

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Polypoidal Choroidal Vasculopathy
Interventions
DRUG

ranibizumab intravitreal injection

liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year

Trial Locations (2)

96701

The Retina Center at Pali Momi, ‘Aiea

96817

Retina Consultants of Hawaii, Honolulu

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Hawaii Pacific Health

OTHER